Engrail Therapeutics Secures $157 Million in Mid-Stage Neuroscience Research Funding

1. Engrail Therapeutics, a mid-stage neuroscience startup, has raised $157 million in funding as reported by Endpoints News on March 19, 2024.
2. The funds are intended to support a mid-stage clinical trial focusing on generalized anxiety.
3. Initially, Engrail aimed to raise $100 million during their Series B round, but due to increased interest and activity within the neuroscience research and development (R&D) sector, they exceeded this goal.
4. The company is working on developing "de-risked" mood disorder treatments, which suggests an emphasis on reducing risks associated with potential therapies.

These details confirm that Engrail Therapeutics successfully secured significant financial backing to advance their work in the field of neuroscience, particularly in addressing generalized anxiety and other mood disorders.